Publication date: Dec 01, 2025
The aim of this study was to elucidate the relationship between HA levels and clinical outcomes, including disease severity and prognosis. A retrospective multicenter cohort analysis was conducted across three medical centers in China from September 2022 to February 2023. Patients with positive nucleic acid for the novel coronavirus were included in the study. The primary endpoint is 28-day mortality. The severity was assessed by the ‘Diagnosis and Treatment Plan for Novel Coronavirus Pneumonia (Trial Version 9)’. Analyses assessed HA correlation with severity (Kendall), predictive value for mortality (logistic regression, ROC, Delong test), and survival differences (KM analysis using a Youden index-derived HA cutoff). A total of 862 patients (median age 72; 58. 47% male) were included in the study, of whom 108 died. Non-survivors were older, more men, lower BMI, and more complicatinos. The overall median HA level was 121. 65 ng/ml, significantly higher in non-survivors(p
Semantics
| Type | Source | Name |
|---|---|---|
| drug | DRUGBANK | Hyaluronic acid |
| disease | MESH | COVID-19 |
| disease | IDO | nucleic acid |
| disease | MESH | Pneumonia |
| drug | DRUGBANK | Saquinavir |